Refine by
Brain Functions Articles & Analysis
47 news found
Ghrelin, widely recognized as the hunger hormone, is now under the spotlight for its role in mental health. Recent studies suggest that this metabolic signal may influence mood, especially in individuals with major depressive disorder (MDD). This connection between ghrelin and emotional states reveals new possibilities for understanding the gut-brain axis. Ghrelin levels rise during fasting ...
Are you restless during sleep at night? Do you often wake up at night due to bad dreams or have difficulty in falling asleep? Are you anxious before you sleep? There are a variety of issues that can hamper proper and restful sleep at night, apart from snoring. According to University of Arizona clinical professor of medicine and dream specialist, Rubin Naiman, PhD, the two key components of good ...
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the SKYLARK Study and further demonstrated the rapid improvements in depressive symptoms observed in the clinical ...
BESA Connectivity 2.0 is just around the corner! As a successor to the best-in-class tool for functional brain connectivity analysis, it comes with a bunch of great new features and improvements. Here are some of the most important news about this software*: Batch processing for both time-frequency and connectivity workflows – analyze your complete subject set in one go, also for ...
EEG in everyday life: As scientists and researchers, we have asked ourselves – what happens in our brain when we play darts or table football? How does it actually work and why can we sometimes not react as fast as we want? We have investigated these interesting activities using BESA software together with mBrainTrain, a manufacturer and pioneer of fully portable, mobile EEG devices, and ...
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) and postpartum depression. The 11 new analyses are being presented at the 2022 Psych Congress in New Orleans, ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, ...
Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...
Ness Ziona, Science Park, May 18, 2022 - Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions, today announced that its scientific founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be presenting at TACA’s Autism Action Conference, taking place virtually from April 8-9, 2022. The ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...
Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological ...
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces its operating results for the first quarter of fiscal year 2022 ended December 31, 2021. First Quarter and Recent Business Updates Submitted clearance ...
CD BioGlcyo, a biotechnology company that specialized in providing glycobiology-related products, analysis, custom synthesis, and design to advance glycobiology research, now provides a comprehensive list of custom carbohydrate synthesis services that can combine chemical and enzymatic methods to quickly compose saccharide-related products. Carbohydrates are the main components and energy ...
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately. Dr. Linda M. Liau is Professor and W. Eugene Stern Chair of the Department of Neurosurgery at the ...
BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope’s innovative point-of-care neuro-technology system available to the 18,000 members, including over 5000 outpatient facilities and senior centers, in Yankee Alliance. BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild ...